A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

The drugmaker accuses Premier Weight Loss of risking patients' health by selling altered, unsterile versions of its ...

Such medications are just one part of a necessary, holistic approach that includes diet, exercise, and addressing significant ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, swelling that can be caused by cancer treatment.

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...